Glaukos Corp (GKOS) valuation against sector peers: P/B 15.0, free-cash-flow yield 0.3%, P/S 15.6.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.

Metric	GKOS	Sector median	vs median
P/E	—	30.6 · n=152	—
P/B	15.0	4.0 · n=305	274% above
P/S	15.6	4.4 · n=297	251% above
EV/EBIT	—	25.8 · n=139	—
Free-cash-flow yield	0.3%	1.4% · n=287	76% below
Dividend yield	0.00%	0.00% · n=358	—
Return on equity	−22.8%	−3.7% · n=306	—
Return on invested capital	—	0.4% · n=275	—
Gross margin	64.8%	61.7% · n=202	5% above
Net debt / EBITDA	—	1.31 · n=146	—

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.

Sector peers

The largest companies of the same sector and region.

Instrument	P/E	P/B	EV/EBIT	Free-cash-flow yield	Dividend yield	Smart Score
LLYEli Lilly & Co	45.4	35.8	—	1.5%	0.6%	7/10
JNJJohnson & Johnson	40.5	8.0	—	3.2%	1.9%	8/10
ABBVAbbVie	80.6	—	33.8	3.6%	3.0%	5/10
UNHUnitedHealth	25.9	3.5	19.1	6.5%	2.2%	9/10
MRKMerck	109.6	8.3	—	4.6%	2.4%	9/10
TMOThermo Fisher Scientific	37.4	4.9	36.7	2.8%	0.3%	10/10
AMGNAmgen	27.9	20.9	25.2	4.2%	2.2%	7/10
GILDGILEAD	—	16.7	—	6.6%	2.0%	5/10
ABTAbbott	28.4	3.4	26.8	4.1%	3.0%	6/10
PFEPfizer	38.7	2.0	—	6.5%	7.3%	1/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 Sep 2026 · filed 28 Oct 2026

Withdraw from contract here · EU consumers: 14 days to withdraw from a purchase.

Cookie settings